grant
Investigating Type I Interferon response and differentiation in FLT3-inhibitor persistent acute myeloid leukemia
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 1 May 2026Deadline 30 Apr 2031
NIHUS FederalResearch GrantFY2026(IFN) α(IFN)-α(IFN)αAML - Acute Myeloid LeukemiaAblationAcute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAddressAlferonAllelesAllelomorphsAllogenicAssayAutomobile DrivingB23Bar CodesBasal Transcription FactorBasal transcription factor genesBenchmarkingBest Practice AnalysisBioassayBiologic ModelsBiological AssayBiological ModelsC-K-RASCRE RecombinaseCRISPR approachCRISPR based approachCRISPR methodCRISPR methodologyCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 technologyCancer GenesCancer-Promoting GeneCancersCas nuclease technologyCell BodyCell Communication and SignalingCell DifferentiationCell Differentiation InhibitionCell Differentiation processCell FunctionCell IsolationCell PhysiologyCell ProcessCell SegregationCell SeparationCell Separation TechnologyCell SignalingCell SurvivalCell ViabilityCellsCellular FunctionCellular PhysiologyCellular ProcessChemicalsClinicalClinical TrialsClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyCombined Modality TherapyCredentialingDNADNA mutationDNMT3aDTR ProteinDataDeoxyribonucleic AcidDetectionDevelopmentDiphtheria Toxin SensitivityDiseaseDisease remissionDisorderDrugsEnterobacteria phage P1 Cre recombinaseEventFLK2FLT3FLT3 geneFLT3 inhibitionFLT3 inhibitorFMS-like tyrosine kinase 3Fms-Related Tyrosine Kinase 3GEM modelGEMM modelGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGenesGeneticGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGenetically Engineered MouseGenomicsGoalsHB-EGF precursorHematopoieticHumanHuman Cell LineIFNIFN AlphaIFN αIFN-αIFNaIFNαInflammationInterferon Alfa-n3Interferon Type IInterferon-αInterferonsIntracellular Communication and SignalingK-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneKRASKRAS2KRAS2 geneKi-RASKinasesKineticsLeukemic CellLeukemic progenitor and stem cellLeukocyte InterferonLymphoblast InterferonLymphoblastoid InterferonLytotoxicityMalignant NeoplasmsMalignant TumorMediatingMedicationMiceMice MammalsMissionModel SystemModelingModern ManMolecularMolecular FingerprintingMolecular ProfilingMonocytic leukemiaMultimodal TherapyMultimodal TreatmentMurineMusMutateMutationMyeloid CellsNPMNPM1NPM1 geneNon-Receptor Type 11 Protein Tyrosine PhosphataseOncogene K-RasOncogenesOncogenicPTK InhibitorsPTK ReceptorsPTP-2 enzymePTP2CPTPN11PTPN11 genePathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhosphotransferase GenePhosphotransferasesPlayPopulationPrediction of Response to TherapyProgenitor Cell TransplantationPropertyProtein Tyrosine Kinase InhibitorsProtein Tyrosine Phosphatase 2CProtein-Tyrosine Phosphatase 2CRASK2RNA ExpressionReceptor Protein-Tyrosine KinasesReceptor Tyrosine Kinase GeneRecurrenceRecurrentRecurrent diseaseRelapseRelapsed DiseaseRemissionReporterResearchResearch SpecimenResolutionRoleSHP2SHP2 PhosphataseSHPTP2STK-1 kinaseSTK1SamplingSchilling's leukemiaShp-2 tyrosine phosphataseSignal InductionSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSourceSpecimenStem Cell TransplantationStem Cell Tyrosine Kinase 1Stem Cell likeStem cell transplantSubcellular ProcessSystemTK InhibitorsTechnologyTherapeuticTranscriptionTranscription Factor Proto-OncogeneTranscription factor genesTransforming GenesTransmembrane Receptor Protein Tyrosine KinaseTransphosphorylasesTransplantationTyrosine Kinase InhibitorTyrosine Kinase Linked ReceptorsTyrosine Kinase ReceptorsTyrosine Phosphatase SHP2acute granulocytic leukemiaacute granulocytic leukemia cellacute myeloblastic leukemia cellacute myelocytic leukemia cellacute myelogenous leukemia cellacute myeloid leukemiaacute myeloid leukemia cellacute nonlymphocytic leukemia cellbacteriophage P1 recombinase Crebarcodebenchmarkbiological signal transductioncell sortingcell typecellular differentiationclinical sequencingcombination therapycombined modality treatmentcombined treatmentcytotoxicitydevelopmentaldiphtheria toxin receptordiptheria toxin receptordrivingdrug/agentenzyme activityfetal liver kinase-2fetal liver kinase-3genetically engineered mouse modelgenetically engineered murine modelgenome mutationhDNA methyltransferase 3ahematopoietic hierarchyhemopoietichuman diseaseimprovedin vivoinnovateinnovationinnovativeinsightinterestkinase inhibitorkinetic modellenslensesleukemialeukemia relapseleukemia stem/initiating cellsleukemia treatmentleukemic progenitorleukemic stem cellleukemic therapyloss of functionmalignancymolecular profilemolecular signaturemouse modelmulti-modal therapymulti-modal treatmentmurine modelmutantneoplasm/canceroncogene addictionpathwaypharmacologicpredict therapeutic responsepredict therapy responsepreventpreventingprogenitor capacityprogenitor cell likeprogenitor transplantationprogenitor-likeprogenitor-like cellrecombinaserecurrent leukemiarelapse patientsresolutionsresponseresponse to therapyresponse to treatmentscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsmall moleculesocial rolestem and progenitor cell transplantationsstem cell characteristicsstem-likestem-like cellstemnesssynergismtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapy predictiontherapy responsetranscription factortransplanttreatment predictiontreatment responsetreatment response predictiontreatment responsivenessv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog
Description preview
PROJECT SUMMARY
Acute myeloid leukemia (AML) is a genetically and cellularly heterogenous disease characterized by the
expansion of hematopoietic cells across a range of cell states from stem-like cells to differentiated myeloid cells.
The most mutated genes in AML are DNMT3A, NPM1 and the receptor tyrosine kinase FLT3. Despite early
clinical…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click